LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Home・Elenco Azioni・Incyte Corp

Incyte Corp

Chiusa

SettoreSettore sanitario

101.34 3.53

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

97.42

Massimo

101.42

Metriche Chiave
By Trading Economics
Entrata	4.1M 303M
Vendite	-234M 1.3B
P/E Media del settore	13.501 49.888
EPS	1.81
Margine di Profitto	23.834
Dipendenti	2,844
EBITDA	-47M 368M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+18.04% upside

Dividendi
By Dow Jones
Utili prossimi	28 lug 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	49M 19B
Apertura precedente	97.81
Chiusura precedente	101.34

Notizie sul Sentiment di mercato

By Acuity

49%

51%

152 / 344 Classifica in Healthcare

Incyte Corp Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

3 giu 2026, 23:22 UTC

Utili

I principali Market Mover

Broadcom Shares Slide Despite Jump in 2Q Revenue on AI Chip Demand -- Update

3 giu 2026, 23:09 UTC

Azioni calde

Stocks to Watch: Broadcom, CrowdStrike, PVH, Petco

3 giu 2026, 20:51 UTC

Utili

Costco Reports 15% Sales Growth in May

3 giu 2026, 20:43 UTC

Utili

Broadcom 2Q Revenue Climbs on AI Chip Demand

3 giu 2026, 23:48 UTC

Discorsi di Mercato

Nikkei May Fall Amid Renewed Concerns About Iran Conflict -- Market Talk

3 giu 2026, 23:48 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

3 giu 2026, 23:35 UTC

Discorsi di Mercato

Oil Futures Fall on Possible Technical Correction -- Market Talk

3 giu 2026, 23:15 UTC

Discorsi di Mercato

Utili

Five Below, Broadcom and Crowdstrike Fall Despite Solid Results -- Market Talk

3 giu 2026, 22:08 UTC

Azioni calde

After-Hours Stocks to Watch: CrowdStrike, Broadcom, Five Below -- WSJ

3 giu 2026, 21:54 UTC

Discorsi di Mercato

Correction to Oil Futures Rise on Concerns About U.S.-Iran Talks Article on June 1

3 giu 2026, 21:18 UTC

Utili

Broadcom's Non-AI Semiconductor Revenue Rose 6% in 2Q, CEO Says

3 giu 2026, 21:15 UTC

Utili

Broadcom CEO: Google Partnership Continues to Be 'Very Substantial'

3 giu 2026, 21:13 UTC

Utili

Broadcom CEO Expects AI Semiconductor Revenue Growth to Continue in Fiscal 2028

3 giu 2026, 21:13 UTC

Utili

Broadcom Continues to Expect AI Semiconductor Revenue of More Than $100B in 2027, CEO Says

3 giu 2026, 21:12 UTC

Utili

Broadcom Expects AI Semiconductor Revenue of $56B This Year, CEO Says

3 giu 2026, 21:09 UTC

Utili

Broadcom CEO: Networking Made Up Almost 40% of AI Revenue in 2Q

3 giu 2026, 21:03 UTC

Utili

Broadcom Stock Falls After Earnings. Here's Why. -- Barrons.com

3 giu 2026, 20:50 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

3 giu 2026, 20:43 UTC

Utili

CrowdStrike Stock Falls Despite Earnings Beat -- Barrons.com

3 giu 2026, 20:39 UTC

Acquisizioni, Fusioni, Takeovers

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 4th Update

3 giu 2026, 20:37 UTC

Acquisizioni, Fusioni, Takeovers

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 3rd Update

3 giu 2026, 20:35 UTC

Utili

Broadcom Stock Falls Despite Record Results -- Barrons.com

3 giu 2026, 20:21 UTC

Acquisizioni, Fusioni, Takeovers

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 2nd Update

3 giu 2026, 20:17 UTC

Utili

Broadcom 2Q Semiconductor Solutions Revenue $15B >AVGO

3 giu 2026, 20:17 UTC

Utili

Broadcom Sees 3Q Semiconductor Revenue From AI $16B >AVGO

3 giu 2026, 20:15 UTC

Acquisizioni, Fusioni, Takeovers

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- Update

3 giu 2026, 20:15 UTC

Utili

Broadcom 2Q Adj EPS $2.44 >AVGO

3 giu 2026, 20:15 UTC

Utili

Broadcom 2Q EPS $1.91 >AVGO

3 giu 2026, 20:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

3 giu 2026, 20:15 UTC

Utili

Broadcom 2Q Rev $22.19B >AVGO

Confronto tra pari

Modifica del prezzo

Incyte Corp Previsione

Obiettivo di Prezzo

By TipRanks

18.04% in crescita

Previsioni per 12 mesi

Media 108.88 USD 18.04%

Alto 135 USD

Basso 75 USD

Basato su 19 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Incyte Corp - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

19 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 19 che hanno fornito valutazioni azionarie a Incyte Corp - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

152 / 344 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation